The Effect of Individualized Precision Therapy Programs in Patients With Biliary Tract Cancer
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Biliary Tract Neoplasms
- Sponsor
- RenJi Hospital
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Overall Survival (OS)
- Last Updated
- 6 years ago
Overview
Brief Summary
This is a prospective cohort study. Patients who meet the inclusion criteria will be enrolled in this study. The samples of biliary tract tumors will be collected. Genome sequencing, mini-PDX and PDX will be performed according to the requirement of individualized precision therapy programs. Suitable drugs will be chose according to drug screening results. OS and PFS will be compared with traditional chemotherapy to evaluate the effect of individualized precision therapy programs.
Detailed Description
In this prospective cohort study, patients who are eligible for inclusion criteria will enroll in the study. After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification, and then to develop individualized precise treatment programs. The investigators hope to achieve the following objectives: ① Through the establishment of Individualized Precision Therapy Programs to improve the overall survival of bile duct malignancy (BTC)； ② To study the molecular typing of the prognosis of biliary malignancy; ③ To construct a database of BTC gene bank, as well as for drug screening information.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Pathological diagnosis of biliary malignancies
- •The expected survival time is longer than 3 months
- •PKS score\> 60 points
- •Willing to take part in the study
Exclusion Criteria
- •Can not or refuse to collect tumor samples
- •Refused to accept the relevant treatment method
Outcomes
Primary Outcomes
Overall Survival (OS)
Time Frame: through study completion, an average of 2 year
The time from surgery to all-cause death
Secondary Outcomes
- Progression-Free Survival (PFS)(through study completion, an average of 2 year)